Literature DB >> 30108765

Synthesis and evaluation of small molecules bearing a benzyloxy substituent as novel and potent monoamine oxidase inhibitors.

Jin-Shuai Lan1, Tong Zhang2, Yun Liu1, Yong Zhang1, Jian-Wei Hou1, Sai-Sai Xie3, Jing Yang1, Yue Ding1, Zhen-Zhen Cai4.   

Abstract

A new series of small molecules bearing a benzyloxy substituent have been designed, synthesized and evaluated for hMAO inhibitory activity in vitro. Most of the compounds were potent and selective MAO-B inhibitors, and were weak inhibitors of MAO-A. In particular, compounds 9e (IC50 = 0.35 μM) and 10e (IC50 = 0.19 μM) were the most potent MAO-B inhibitors, and exhibited the highest selectivity for MAO-B (9e, SI > 285.7-fold and 10e, SI = 146.8-fold). In addition, the structure-activity relationships for MAO-B inhibition indicated that electron-withdrawing groups in the open small molecules were more suitable for MAO-B inhibition, and substitutions at the benzyloxy of the open small molecules, particularly with the halogen substituted benzyloxy, were more favorable for MAO-B inhibition. Molecular docking studies have been done to explain the potent MAO-B inhibition of the open small molecules. Furthermore, the representative compounds 9e and 10e showed low neurotoxicity in SH-SY5Y cells in vitro. So the small molecules bearing the benzyloxy substituent could be used to develop promising drug candidates for the therapy of neurodegenerative diseases.

Entities:  

Year:  2017        PMID: 30108765      PMCID: PMC6072412          DOI: 10.1039/c6md00586a

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  24 in total

Review 1.  Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.

Authors:  Jack J Chen; David M Swope; Khashayar Dashtipour
Journal:  Clin Ther       Date:  2007-09       Impact factor: 3.393

2.  A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.

Authors:  Chuanjun Lu; Qi Zhou; Jun Yan; Zhiyun Du; Ling Huang; Xingshu Li
Journal:  Eur J Med Chem       Date:  2013-02-08       Impact factor: 6.514

3.  cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties.

Authors:  A W Bach; N C Lan; D L Johnson; C W Abell; M E Bembenek; S W Kwan; P H Seeburg; J C Shih
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

4.  Tissue distribution of human monoamine oxidase A and B mRNA.

Authors:  J Grimsby; N C Lan; R Neve; K Chen; J C Shih
Journal:  J Neurochem       Date:  1990-10       Impact factor: 5.372

5.  Monoamine oxidase inhibition by C4-substituted phthalonitriles.

Authors:  Clarina I Manley-King; Jacobus J Bergh; Jacobus P Petzer
Journal:  Bioorg Chem       Date:  2011-10-29       Impact factor: 5.275

Review 6.  Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism.

Authors:  A S Kalgutkar; N Castagnoli
Journal:  Med Res Rev       Date:  1995-07       Impact factor: 12.944

7.  Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid.

Authors:  R M Geha; I Rebrin; K Chen; J C Shih
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

8.  PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice.

Authors:  Virgili Perez; Mercedes Unzeta
Journal:  Neurochem Int       Date:  2003-02       Impact factor: 3.921

Review 9.  Biochemistry and genetics of monoamine oxidase.

Authors:  W Weyler; Y P Hsu; X O Breakefield
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

10.  Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class.

Authors:  Claudia Binda; Frantisek Hubálek; Min Li; Yaacov Herzig; Jeffrey Sterling; Dale E Edmondson; Andrea Mattevi
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

View more
  1 in total

1.  Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors.

Authors:  Bijo Mathew; Seung Cheol Baek; Della Grace Thomas Parambi; Jae Pil Lee; Monu Joy; P R Annie Rilda; Rugma V Randev; P Nithyamol; Vijitha Vijayan; Sini T Inasu; Githa Elizabeth Mathew; Krishnakumar K Lohidakshan; Girish Kumar Krishnan; Hoon Kim
Journal:  Medchemcomm       Date:  2018-09-25       Impact factor: 3.597

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.